Preferred Label : tepmetko;
Origin ID : M000750387;
Related record
- See also inter- (CISMeF)
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/tepmetko-cancer-du-poumon-non-a-petites-cellules-6026.html
2022
false
false
false
Canada
French
insurance, health, reimbursement
drug evaluation
canada
tepmetko
Tepotinib Hydrochloride
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
MET Exon 14 Skipping Mutation
---
https://www.ema.europa.eu/en/medicines/human/EPAR/tepmetko
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tepotinib
tepotinib
tepotinib
antineoplastic agents
antineoplastic agents
bronchial neoplasms
carcinoma, non-small-cell lung
drug approval
europe
pregnancy
breast feeding
drug interactions
Product containing precisely tepotinib (as tepotinib hydrochloride) 225 milligram/1
each conventional release oral tablet (clinical drug)
tepmetko
Tepotinib Hydrochloride
adult
bronchial neoplasms
carcinoma, non-small-cell lung
mutation
MET Exon 14 Skipping Mutation
proto-oncogene proteins c-met
protein kinase inhibitors
protein kinase inhibitors
administration, oral
drug evaluation, preclinical
Tyrosine Kinase Inhibitors
---
